180 related articles for article (PubMed ID: 35289334)
21. The Expression Level of
Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
[TBL] [Abstract][Full Text] [Related]
22. CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival.
Xu J; Wei L; Liu H; Lei Y; Zhu Y; Liang C; Sun G
Cancer Invest; 2022 Mar; 40(3):228-233. PubMed ID: 35020560
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Nishimura K; Nishio K; Hirosuna K; Komura K; Hayashi T; Fukuokaya W; Ura A; Uchimoto T; Nakamura K; Fukushima T; Yano Y; Takahashi N; Nakamori K; Kinoshita S; Matsunaga T; Tsutsumi T; Tsujino T; Taniguchi K; Tanaka T; Uehara H; Takahara K; Inamoto T; Hirose Y; Kimura T; Egawa S; Azuma H
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039462
[TBL] [Abstract][Full Text] [Related]
24. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
25. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
26. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
30. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
[TBL] [Abstract][Full Text] [Related]
31. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulators of programmed death-ligand 1 expression in human cancers.
Kumar S; Sharawat SK
Transl Res; 2018 Dec; 202():129-145. PubMed ID: 30401465
[TBL] [Abstract][Full Text] [Related]
33. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
34. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.
Al-Chaqmaqchi H; Sadeghi B; Abedi-Valugerdi M; Al-Hashmi S; Fares M; Kuiper R; Lundahl J; Hassan M; Moshfegh A
PLoS One; 2013; 8(4):e60367. PubMed ID: 23593203
[TBL] [Abstract][Full Text] [Related]
35. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
36. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
37. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms Controlling PD-L1 Expression in Cancer.
Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
[TBL] [Abstract][Full Text] [Related]
39. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Masugi Y; Nishihara R; Yang J; Mima K; da Silva A; Shi Y; Inamura K; Cao Y; Song M; Nowak JA; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig S; Fuchs CS; Qian ZR; Ogino S
Gut; 2017 Aug; 66(8):1463-1473. PubMed ID: 27196573
[TBL] [Abstract][Full Text] [Related]
40. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
